Skip to main content
Journal of Experimental & Clinical Cancer Research : CR logoLink to Journal of Experimental & Clinical Cancer Research : CR
. 2020 Feb 17;39:35. doi: 10.1186/s13046-020-1538-8

Retraction Note: Receptor tyrosine kinase inhibitor Sunitinib and integrin antagonist peptide HM-3 show similar lipid raft dependent biphasic regulation of tumor angiogenesis and metastasis

Jialiang Hu 1,2,#, Wenjing Wang 1,#, Chen Liu 1,2, Mengwei Li 1,2, Edouard Nice 3, Hanmei Xu 1,2,
PMCID: PMC7025398  PMID: 32066476

Retraction Note: J Exp Clin Cancer Res

https://doi.org/10.1186/s13046-019-1324-7

The authors have retracted this article [1] because the bands shown in Fig. 5 panel D for GTP-RhoA/Control, GTP-RhoA/Sunitinib (2 and 64 nM) and GTP-RhoA/HM-3 (4.5 and 72 uM) are not data generated as part of this study. All authors agree to this retraction.

Footnotes

Jialiang Hu and Wenjing Wang contributed equally to this work.

Reference

  • 1.Hu J, Wang W, Liu C, et al. Receptor tyrosine kinase inhibitor Sunitinib and integrin antagonist peptide HM-3 show similar lipid raft dependent biphasic regulation of tumor angiogenesis and metastasis. J Exp Clin Cancer Res. 2019;38:381. doi: 10.1186/s13046-019-1324-7. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]

Articles from Journal of Experimental & Clinical Cancer Research : CR are provided here courtesy of BMC

RESOURCES